On one hand, IL-21 has demonstrated anti-DLBCL activity through the activation of STAT3-c-Myc signaling pathway and downregulation of the anti-apoptotic Bcl-2/Bcl-XL genes [157,159]. The gene discussed is BCL2L1; the disease is diffuse large B-cell lymphoma.